Vanguard Group Inc Satsuma Pharmaceuticals, Inc. Transaction History

Vanguard Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.61 - $5.06 $6,787 - $56,302	11,127 Added 1.22%	920,517 $828,000
Q3 2022 Nov 14, 2022	BUY	$4.19 - $7.95 $1.13 Million - $2.14 Million	269,026 Added 42.01%	909,390 $5.46 Million
Q2 2022 Aug 12, 2022	SELL	$2.59 - $4.3 $20,637 - $34,262	-7,968 Reduced 1.23%	640,364 $2.65 Million
Q1 2022 May 13, 2022	SELL	$3.78 - $5.32 $24,622 - $34,654	-6,514 Reduced 0.99%	648,332 $2.46 Million
Q4 2021 Feb 14, 2022	BUY	$4.15 - $6.24 $34,581 - $51,997	8,333 Added 1.29%	654,846 $2.95 Million
Q3 2021 Nov 12, 2021	BUY	$4.54 - $7.17 $10,042 - $15,860	2,212 Added 0.34%	646,513 $3.01 Million
Q2 2021 Aug 13, 2021	BUY	$4.8 - $7.25 $3.09 Million - $4.67 Million	644,301 New	644,301 $4.54 Million

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.